ORIGINAL RESEARCH

Measuring Sleep Stages and Screening for Obstructive Sleep Apnea with a Wearable Multi-Sensor System in Comparison to Polysomnography

Shuang-Jiang Zhou¹,*, Rui Yang^{2,*}, Lei-Lei Wang¹, Meng Qi¹, Xiao-Fei Yuan², Ting-Ting Wang³, Tian-He Song⁴, Yun-Yue Zhuang⁴, Hong-Juan Li¹, Yun-Long Tan¹, Xue Wang², Jing-Xu Chen¹

¹Sleep Medicine Center, Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, People's Republic of China; ²Beijing Anding Hospital, Capital Medical University, Beijing, People's Republic of China; ³School of Mental Health, Bengbu Medical College, Bengbu, People's Republic of China; ⁴Department of Psychology, Chengde Medical University, Chengde, People's Republic of China

*These authors contributed equally to this work

Correspondence: Xue Wang, Beijing Anding Hospital, Capital Medical University, Beijing, 100088, People's Republic of China, Tel +86-10-58303034, Email xuew37@ccmu.edu.cn; Jing-Xu Chen, Beijing HuiLongGuan Hospital, Peking University HuiLongGuan Clinical Medical School, Beijing, 100096, People's Republic of China, Tel +86-10-83024278, Email chenjx1110@163.com

Objective: To assess the performance of a wearable multi-sensor system (SensEcho) in comparison to polysomnography (PSG) in measuring sleep stages and searching for obstructive sleep apnea (OSA).

Methods: Participants underwent overnight simultaneous monitoring using SensEcho and PSG in a sleep laboratory. SensEcho analyzed the recordings spontaneously, and PSG was assessed as per standard guidelines. The degree of snoring was evaluated according to the guidelines for the diagnosis and treatment of OSA hypopnea syndrome (2011 revision). The Epworth Sleepiness Scale (ESS) was used to assess general daytime sleepiness.

Results: This study included 103 Han Chinese, 91 of whom (age 39.02 ± 13.84 years, body mass index 27.28 ± 5.12 kg/m2, 61.54% male) completed the assessments. The measures of total sleep time (P = 0.198); total wake time (P = 0.182); shallow sleep (P = 0.297), deep sleep (P = 0.422), rapid eye movement sleep (P = 0.570), and awake (P = 0.336) proportions were similar between SensEcho and PSG. Using an apnea-hypopnea index (AHI) cutoff of \geq 5 events/h, the SensEcho had 82.69% sensitivity and 89.74% specificity. Almost the same results were obtained at an AHI threshold of \geq 15 events/h. Although the specificity increased to 94.67%, it decreased to 43.75% at an AHI cutoff of \geq 30 events/h.

Conclusion: This study demonstrated that SensEcho can be used to evaluate sleep status and screen for OSA. Nevertheless, improving the accuracy of its assessment of severe OSA and further testing its effectiveness in community and home environments is necessary.

Keywords: wearable multi-sensor system, polysomnography, sleep stages, obstructive sleep apnea

Introduction

Sleep disorders are an important public health problem with significant adverse consequences to individual health and are a significant economic burden for society;^{1,2} therefore, they have attracted widespread attention. Sleep disorders comprise a wide range of diseases, and the diagnosis of many of their subtypes requires the help of objective indicators.³ Currently, polysomnography (PSG) is an acknowledged tool for measurement of sleep.^{4,5} This technique uses collection of many electrodes attached to the surface of the body, each of which measures physiological parameters of sleep, including of the brain, eye, muscle, heart, respiratory activity, and oxygen saturation, throughout the night.^{5,6}

353

However, with the increase in its use and in-depth research, the limitations of PSG have gradually been recognized. First, the procedure is complicated and time consuming. Second, professional sleep technicians are required to monitor and interpret the data. Third, the body is covered with many electrodes and sensors, which causes obvious discomfort to patients, and finally the discomfort in monitoring sleep in a strange environment, given the need to monitor patients in a specific sleep laboratory. These interfere with the normal sleep of patients and cannot reflect the sleep situation in real life.^{6–8} Therefore, a convenient, comfortable, and interference-free sleep monitoring method is essential in this field.

In recent years, clinicians and researchers have been trying to measure sleep or waking states using wrist actigraphy.^{9–} ¹³ This technique measures wrist movement to evaluate sleep or wakefulness, that is accomplished by the accelerometer in the worn device.¹⁴ Compared to PSG, this method supports sleep research on a larger scale and promotes cheap and uninterrupted sleep measurements without causing disturbance. This technique can also be conveniently used in a wide range of environments and locations.^{15–18} The opportunities for extensive participation rates could enhance the universality of the results, and makes longitudinal and repeated measurement designs more possible. However, there is limited validation with actigraphy compared to the gold standard of PSG; for instance, most actigraphy devices lack respiratory parameters.^{19,20} Compared with PSG, it is well known that actigraphy overestimates sleep and underestimates wake-up time,^{13,21} and the evaluation of sleep stage is often inaccurate.¹⁴ As sleep research continues to receive increasing attention, researchers require a series of effective technologies beyond PSG.

A new wearable multi-sensor system (SensEcho; SensEcho-5A, Beijing SensEcho Sci & Tech Co., Ltd., Beijing, China) was designed to assess sleep stages and respiratory events during sleep. The objective of this research was to assess the correspondence between SensEcho and PSG in the discrimination of sleep stages and searching for obstructive sleep apnea (OSA). In our study, the accuracy, sensitivity, and specificity were analyzed and compared between SensEcho and PSG.

Materials and Methods

Study Population and Design

This is a prospective study. Subjects with suspicious OSA, who had never been diagnosed or treated for their sleep problems, were recruited at the Sleep Medicine Center from Beijing HuiLongGuan Hospital, Beijing, China. One hundred and three adults aged 18–65 years participated in this study from August 1, 2021 to February 28, 2022. After removing missing data from polysomnography (PSG) or SensEcho measurements, 91 subjects were included in the analysis. Individuals were excluded if they met one or more of the following conditions: (1) serious arrhythmia, wearing auxiliary electronic products such as cardiac pacemakers, (2) respiratory failure and other related diseases, (3) unstable medical condition or psychiatric disorder, (4) incomplete fingers rendering them unable to be monitored by percutaneous oxygen saturation (SpO₂), (5) inability to independently cooperate with the test operation, and (6) other situations that the researcher believes make an individual unsuitable to participate in this clinical trial.

Participants slept in a sleep ward with a wearable multi-sensor system (SensEcho; SensEcho-5A, Beijing SensEcho Sci & Tech Co., Ltd., Beijing, China) and PSG (SOMNOscreenTM plus, Somnomedics GmbH, Randersacker, Germany) for one night. All devices were worn simultaneously during all sleep episodes. During the falling-asleep stage, the light is turned off in the room where the subjects are located (the specific time of lights-off is adjusted according to the subjects' sleep habits) and the subjects were required to turn off their mobile phones during the entire sleep period to prevent it from affecting sleep and the monitoring quality. During the monitoring period, the sensitivity of devices was confirmed using the monitoring software to ensure the normal collection of data. The next day, after the subjects got up, they turned on the light, and turned off and removed the collection equipment. There was no outside interference while collecting data, and participants were not allowed to use medications for their sleep.

The research has been approved by the Ethics Committee of Beijing HuiLongGuan Hospital, and informed consent was signed by each participant. This study was conducted in accordance with the Declaration of Helsinki.

SensEcho Measures

We used a wearable vest multi-sensor system (SensEcho) to capture single-lead electrocardiogram (ECG) signals and thoracoabdominal movement signals. A 3-axis accelerometer and a finger pulse oximeter were integrated into the system to capture posture and blood oxygen levels. A bidirectional long short-term memory (BLSTM) network was used to classify the four sleep stages. The Sleep Heart Health Study (SHHS) was used for model training.^{22,23}

Two 16 units-BLSTM layers and a well-connected layer, which represent the transition of the four sleep-stage classes, constituted the network architecture. A total of 152 features were recorded from the single-lead ECG and respiratory signals and were further fed into the BLSTM. SensEcho synchronously recorded the participants' data on single-lead ECG, respiration, posture, and SpO₂ during the monitoring period. Subsequently, 30-second epoch sleep stages (wake, shallow sleep, deep sleep, and rapid eye movement [REM] sleep), sleep-disordered breathing events, apnea-hypopnea index (AHI), etc. were obtained by analyzing the physiological data from the SensEcho software (Figure 1).

PSG Measures

PSG is a method used for detecting and recording physiological changes during sleep. According to the standards of the American Academy of Sleep Medicine (AASM), PSG records the following indicators: electroencephalogram (EEG), electrooculogram (EOG), chin electromyogram, leg electromyogram, ECG, pressure (flow and snore), flow thermistor, effort (thorax/abdomen), SpO₂, pulse rate, body position, and movement (sleep/wake determination). The sampling rate was 512 Hz with a 16-bit resolution. PSG recordings were evaluated by the same registered polysomnographic technologist (RPSGT) using software in accordance with the AASM scoring criteria.²⁴

Snoring Severity

The degree of snoring was evaluated according to the guidelines for the diagnosis and treatment of obstructive sleep apnea hypopnea syndrome (2011 revision) formulated by the Sleep Respiratory Disease Group of the Chinese Thoracic Society in 2011.²⁵ Never snoring: 0 points; mild snoring: the breathing sound is heavier than that of normal people, 1 point will be recorded; moderate snoring: the loud degree of snoring is greater than the voice of ordinary people, 2 points; severe snoring: snoring is so loud that people in the same room cannot sleep, 3 points will be recorded.

Daytime Sleepiness

General sleepiness during the day was assessed using the Epworth Sleepiness Scale (ESS). The ESS is a self-evaluated scale that asks about the likelihood of falling asleep in various situations.^{26,27} The total ESS score ranges from 0–24. Higher scores indicate higher risks of falling asleep. If the ESS score was > 10 points, it was rated as excessive sleepiness.



Figure I Example of wearable vest multi-sensor system and schematic diagram of sleep stages and respiratory events detection algorithm. Abbreviations: ECG, electrocardiogram; SPO₂, percutaneous oxygen saturation; LSTM, long short-term memory; REM, rapid eye movement.

Statistical Analyses

The Statistical Package for the Social Sciences (SPSS) 26.0 and GraphPad Prism 8.0 were used for statistical analyses. Normally distributed continuous variables are expressed as mean \pm standard deviation (M \pm SD), and categorical variables are expressed as counts and percentages. Pearson's correlation analysis was used to analyze the correlation between PSG and SensEcho by monitoring AHI and sleep-related indicators. Paired *t*-tests and Bland-Altman plots were used to analyze the consistency between PSG and SensEcho while monitoring AHI and sleep-related indicators. Sensitivity, specificity, positive/negative predictive value of the SensEcho AHI for the diagnostic characteristics of OSA were calculated using PSG AHI thresholds of \geq 5, \geq 15, and \geq 30 (events/h) as the cut-off value. Sensitivity and specificity were further analyzed using ROC curve analysis. The Youden index was calculated to determine the optimal cutoff value of SensEcho AHI were also calculated at the optimal cut-off value for mild, moderate, and severe OSA.

Results

Out of the 103 adults recruited for the study, 91 of whom (aged 39.02 ± 13.84 and with a mean body mass index of 27.28 ± 5.12 kg/m²) fulfilled the study inclusion criteria and completed the assessments were considered for analysis. Of these, 56 (61.54%) were male and 58 (63.74%) reported at least a moderate level of snoring. Subjects had an average ESS score of 7.30 ± 4.98 . Demographic data of the subjects are presented in Table 1.

Time in bed, sleeping time, awake time, sleep efficiency, wake, shallow sleep (non-REM stage 1 [N1] + non-REM stage 2 [N2]), deep sleep (non-REM stage 3 [N3]), REM sleep stage, AHI, and SPO₂ measured using SensEcho were compared to those from PSG (Table 2 and <u>Table S1</u>). There was no difference between the SensEcho and PSG in the time spent in bed (8.15 ± 1.06 versus [vs] 8.15 ± 1.07 ; P = 0.859), total sleep time (6.34 ± 1.40 vs 6.42 ± 1.28 ; P = 0.198), total wake time (1.73 ± 1.29 vs 1.82 ± 1.53 ; P = 0.182), and sleep efficiency (79.38 ± 14.39 vs 78.63 ± 16.56 ; P = 0.315). Results revealed that the wake (20.62 ± 14.39 vs 21.34 ± 16.54 ; P = 0.336), shallow sleep (69.96 ± 11.87 vs 69.09 ± 12.60 ; P = 0.297), deep sleep (16.12 ± 12.66 vs 16.62 ± 13.10 ; P = 0.422), and REM sleep (14.06 ± 7.33 vs 14.28 ± 7.74 ; P = 0.570) proportions of the participants have no difference between the

n (%)/ M ± SD					
56 (61.54%)					
35 (38.46%)					
39.02 ± 13.84					
53 (58.24%)					
29 (31.87%)					
9 (9.89%)					
168.22 ± 7.45					
77.83 ± 18.09					
27.28 ± 5.12					
12 (13.19%)					
14 (15.38%)					
37 (40.66%)					
28 (30.77%)					
33 (36.26%)					
33 (36.26%)					
25 (27.47%)					
7.30 ± 4.98					

Table IThe General DemographicCharacteristics, Snoring, and Sleepinessof Participants

Abbreviations: BMI, body mass index; ESS, Epworth Sleepiness Scale.

Variables	SensEcho	PSG	$\overline{d} \pm Sd$	t	P	Cohen's D
Time in bed (h)	8.15 ± 1.06	8.15 ± 1.07	-0.002 ± 0.08	-0.178	0.859	0.03
Total sleep time (h)	6.34 ± 1.40	6.42 ± 1.28	0.08 ± 0.61	1.298	0.198	0.13
Total wake time (h)	1.73 ± 1.29	1.82 ± 1.53	-0.08 ± 0.60	-1.345	0.182	0.13
Sleep efficiency (%)	79.38 ± 14.39	78.63 ± 16.56	0.75 ± 7.11	1.011	0.315	0.11
Wake (%)	20.62 ±14.39	21.34 ± 16.54	-0.72 ± 7.12	-0.967	0.336	0.10
Shallow sleep (%)	69.96 ± 11.87	69.09 ± 12.60	0.87 ± 7.92	1.048	0.297	0.11
Deep sleep (%)	16.12 ± 12.66	16.62 ± 13.10	-0.50 ± 5.93	-0.806	0.422	0.08
REM sleep (%)	14.06 ± 7.33	14.28 ± 7.74	-0.22 ± 3.66	-0.570	0.570	0.06
AHI (events/h)	12.05 ± 15.11	14.51 ± 17.87	-2.46 ± 8.29	-2.830	0.006	0.30
5–15	8.05 ± 6.12	8.16 ± 2.08	-0.11 ± 6.74	-0.075	0.941	0.02
> 15–30	19.32 ± 11.42	21.09 ± 3.86	-1.77 ± 9.21	-0.746	0.468	0.19
> 30	33.70 ± 18.91	47.21 ± 15.59	-13.51 ± 9.33	-5.789	0.000	1.45
Obstructive respiratory events	57.78 ± 64.00	29.05 ± 65.32	28.73 ± 48.29	5.675	<0.001	0.59
Hypopnea count	14.02 ± 36.05	51.37 ± 58.75	-37.35 ± 54.50	-6.538	<0.001	0.69
Total respiratory events	71.68 ± 87.62	83.90 ± 107.73	-12.22 ± 53.29	-2.188	0.031	0.23
Longest apnea time (s)	75.73 ± 43.44	51.93 ± 29.80	23.81 ± 41.41	5.484	<0.001	0.57
Mean SpO ₂ (%)	95.53 ± 1.58	95.68± 1.58	-0.53 ± 3.84	-1.310	0.194	0.14
Minimum SpO ₂ (%)	85.73 ± 6.62	86.25 ± 7.38	-0.09 ± 1.27	-0.660	0.511	0.07
SpO ₂ < 90% (min)	11.55 ± 26.88	11.43 ± 24.42	0.12 ± 18.19	0.063	0.950	0.01

Table 2 Comparison of Sleep Stages and Respiratory Parameters Observed Using SensEcho and PSG

Abbreviations: REM, rapid eye movement; AHI, apnea-hypopnea index; PSG, polysomnography; SpO₂, percutaneous oxygen saturation; h, hour; min, minute; s, second; %, percentage.

measurements by SensEcho and those by PSG. A significant difference between the SensEcho and PSG in AHI > 30 (33.70 \pm 18.91 vs 47.21 \pm 15.59; P = 0.000), but when 5 \leq AHI \leq 30, there was no difference between them. Whereas there were no significant differences in Mean SpO₂, Minimum SpO₂, and SpO₂ \leq 90% between SensEcho and PSG.

As shown in Figure 2, a high degree of correlation between the recordings from SensEcho and PSG was found for the following measures: sleep efficiency (r = 0.917; P < 0.001); wake (r = 0.917; P < 0.001), shallow sleep (r = 0.792; P < 0.001), deep sleep (r = 0.895; P < 0.001), and REM sleep (r = 0.883; P < 0.001) proportions; and AHI (r = 0.887; P < 0.001). Bland-Altman analysis showed a mean difference of -0.01 (95% confidence interval, -0.14 to 0.12; Figure 3A) for sleep efficiency, 0.01 (95%



Figure 2 Compare the relevance between manually edited parameters on SensEcho recording and PSG. ((A) Scatterplot of sleep efficiency on SensEcho compared to PSG; (B) Scatterplot of wake on SensEcho compared to PSG; (C) Scatterplot of shallow sleep on SensEcho compared to PSG; (D) Scatterplot of deep sleep on SensEcho compared to PSG; (E) Scatterplot of REM sleep on SensEcho compared to PSG; (F) Scatterplot of AHI on SensEcho compared to PSG). Abbreviations: PSG, polysomnography; REM, rapid eye movement; AHI, apnea-hypopnea index.



Figure 3 Compare the coherence between manually edited parameters on SensEcho recording and PSG. ((**A**) Bland-Altman plot of sleep efficiency on SensEcho compared to PSG; (**B**) Bland-Altman plot of shallow sleep on SensEcho compared to PSG; (**D**) Bland-Altman plot of shallow sleep on SensEcho compared to PSG; (**D**) Bland-Altman plot of shallow sleep on SensEcho compared to PSG; (**D**) Bland-Altman plot of shallow sleep on SensEcho compared to PSG; (**D**) Bland-Altman plot of shallow sleep on SensEcho compared to PSG; (**D**) Bland-Altman plot of All on SensEcho compared to PSG. (**A**) Bland-Altman plot of All on SensEcho compared to PSG. (**A**) SensEcho compared to PSG; (**D**) Bland-Altman plot of SensEcho compared to PSG; (**D**) Bland-Altman plot of SensEcho compared to PSG; (**D**) SensEcho comp

confidence interval, -0.12 to 0.13; Figure 3B) for wake, -0.01 (95% confidence interval, -0.016 to 0.15; Figure 3C) for shallow sleep, 0.01 (95% confidence interval, -0.11 to 0.12; Figure 3D) for deep sleep, 0.002 (95% confidence interval, -0.07 to 0.07; Figure 3E) for REM sleep, and 2.46 (95% confidence interval, -13.79 to 18.71; Figure 3F) for AHI, between recordings from SensEcho and PSG. Respectively, after the calculations, 95.6%, 95.6%, 96.7%, and 98.9% points were settled in the limits of coincidence and its 95% confidence interval, which indicated a high level of coincidence between SensEcho and PSG measures for overall sleep efficiency, wake, shallow sleep, deep sleep, and REM sleep, except for AHI (93.4%).

Table 3 shows the comparisons of the diagnostic characteristics of SensEcho AHI based on the cutoff value of PSG AHI with variable severity criteria at 5, 15, and 30 events/h. Figure 4 shows the corresponding ROC curves. With an

АНІ	Prevalence Sen	Sensitivity	Exact 95% CI		Specificity	Exact 95% CI		PPV	NPV
(Events/h)	(%)	(%)	LB	UB	(%)	LB	UB	(%)	(%)
≥ 5	57.14	82.69	69.18	91.31	89.74	74.84	96.66	91.48	79.54
≥ 15	31.87	79.31	59.74	91.29	87.10	75.60	93.87	74.19	90.00
≥ 30	17.58	43.75	20.75	69.45	94.67	86.19	98.28	63.64	88.75

Table 3 Prevalence, Sensitivity, Specificity, PPV, and NPV for Different Cutoff of the SensEcho Recording vs PSG

Abbreviations: AHI, apnea-hypopnea index; CI, confidence interval; LB, lower bound; UB, upper bound; PPV, positive predictive value; NPV, negative predictive value.

AHI cutoff of \geq 5 events/h, SensEcho recording had 82.69% sensitivity, 89.74% specificity, and an AUC of 0.922. Almost the same results were obtained at an AHI threshold of \geq 15 events/h. Although the specificity increased to 94.67% and the AUC increased to 0.936, the specificity decreased to 43.75% at an AHI cut-off of \geq 30 events/h. According to the PSG diagnostic criterion of AHI > 5 events/h, the appropriate diagnostic cutoff value of SensEcho was 4.8 events/h, whose sensitivity is 84.62% and specificity is 89.75%. For moderate to severe OSA (AHI > 15 events/h), the SensEcho cut-off was 11.2 events/h, sensitivity was 87.10%, and specificity was 88.34%, as shown in Table 4.

Discussion

This study is a clinical validation study for measuring the sleep stages and presence of obstructive events using a wearable vest multi-sensor system, SensEcho, which compared the data to simultaneously obtained PSG information. In the present study, specific variations in the accuracy, sensitivity, and specificity values were characterized. Overall, SensEcho has good accuracy in distinguishing sleep or wakefulness and for monitoring sleep stages. The total sleeping time, total awake time, shallow sleep, deep sleep, REM sleep, and wakefulness were consistent with the manual mapping of the PSG. Although SensEcho had a good correlation with PSG in the diagnosis of AHI, the consistency was unsatisfactory. SensEcho has high specificity for OSA screening. When AHI was \geq 5 and \geq 15, the sensitivity was good. When AHI was \geq 30, the sensitivity was poor. SensEcho has a relatively good negative predictive value (NPV) for OSA but a poor positive predictive value (PPV), especially when AHI \geq 30. This may be due to the fact that the proportion of health testers in the training set is more than that of patients with severe OSA, so the accuracy for AHI scores greater than 30 decreases. According to this study, the AHI correction thresholds for screening OSA using SensEcho were mild OSA, \geq 4.8; moderate OSA, \geq 11.2; and severe OSA, \geq 17.7.

The SensEcho was designed to detect participants' ECG, respiratory movement, SpO₂, body motion, and posture, as well as to use a specific algorithm to obtain the sleep status and sleep-related respiratory indicators of the subjects. In



Figure 4 Receiver operating characteristic curves for the SensEcho estimated AHI vs PSG AHI. Abbreviations: AHI, apnea-hypopnea index; AUC, area under the curve.

AHI (Events/h)	SensEcho Cutoff (Events/h)	AUC	Sensitivity (%)	Specificity (%)	PPV (%)	NPV (%)
≥ 5	4.8	0.922	84.62	89.75	84.62	89.74
≥ 15	11.2	0.949	87.10	88.34	86.67	86.89
≥ 30	17.7	0.936	87.50	89.34	87.50	87.67

Table 4 Best Cutoffs for Different OSA Severity

Abbreviations: AHI, apnea-hypopnea index; AUC, area under the curve; PPV, positive predictive value; NPV, negative predictive value.

terms of sleep staging, the SensEcho used in this study had better results than similar devices used in most previous studies. For example, the partial-PSG system used in previous studies included Zeo (Newton, MA, USA).^{28,29} The Zeo system can provide convincing sleep scoring for REM sleep and light and deep sleep. However, the system could not correctly detect the wake periods. In another study conducted with non-contact radar technology, Somnofy (VitalThings AS, Norway) found the sensitivity was 0.97 and specificity was 0.72, respectively. Sleeping stage differentiation for Somnofy was 0.75 for N1/N2, 0.74 for N3, and 0.78 for REM.³⁰ Wrist actigraphy cannot distinguish sleep stages but can simply distinguish between sleep and wakefulness.⁴ Therefore, SensEcho has greater advantage over wrist actigraphy due to its ability to differentiate sleep stages. However, it should be noted that SensEcho training model has extracted features from ECG and respiratory signals, a large part of which was heart rate variability (HRV), and the HRV characteristic parameters of patients with severe arrhythmia were relatively different from normal people, and there were many statistical deviations. Our model training set is mainly composed of non-arrhythmia testers, so sleep staging is less effective for patients with severe arrhythmias. In terms of respiratory monitoring, SensEcho is slightly inferior to other portable devices that can monitor respiratory function, such as OrbSense (Megahealth Medical, Inc., Zhejiang, China). Central sleep apnea (CSA) mainly manifests as repeated interruptions or weakening of respiratory airflow and ventilation during sleep, often related to other medical problems, especially heart failure, stroke, and the use of opioid drugs. SensEcho uses chest and abdominal breathing signals to estimate respiratory airflow, but there is little confidence in the judgment of CSA. Therefore, SensEcho currently can not detect CSA precisely. This monitoring equipment also has good sensitivity and specificity when AHI is $\geq 30^{31}$ SensEcho is superior to wrist actigraphy in terms of respiration; as wrist actigraphy has no blood oxygen and respiratory indicators, it is unable to screen for OSA.

One advantage of the SensEcho is its design as a sleeping monitoring vest, without head and leg electrodes and nasal airflow tubes connected to the patient. This factor greatly reduces the impact on patients' sleep and may allow for relatively natural sleep than in the traditional setup. In addition, it needs fewer settings, so it is possible to easily test sleep-related breathing disorders at home, which helps in outpatient diagnosis and expands the diagnostic capabilities. Once again, SensEcho is unobtrusive and can be worn throughout the day for over a week. This makes SensEcho more conducive to the long-term monitoring of patterns in sleeping rhythm.^{32,33}

This study has a few limitations. First of all, it was performed in a laboratory rather than in a home environment. There are some chances for SensEcho to behave differently in the home environment. Second, the current research focuses on ethnically Han patients with a low body mass index; therefore, the current research results are limited with regards to other populations. Finally, the overall AHI of the participants was low, and the recognition rate of SensEcho in patients with AHI \geq 30 was poor. Therefore, in the future, it will be helpful to employ machine learning techniques to the database to improve the recognition rate of AHI equipment.

Conclusions

This study demonstrated the application of SensEcho as a portable monitoring device in the laboratory to evaluate sleep staging and detect sleep apnea in patients with suspicious OSA. The system may help with evaluating sleep status and screen for OSA in different settings. However, it is necessary to further improve the accuracy of its assessment of severe OSA and test its effectiveness in community and home environments.

Data Sharing Statement

The data that support the findings of this study are available from the corresponding author upon reasonable request.

Ethics Approval and Consent to Participate

This study was approved by the Ethics Committee of Beijing Huilongguan Hospital and we made sure that each participant had signed written informed consent.

Acknowledgments

We would like to thank Editage (www.editage.cn) for English language editing.

Funding

This research was supported by the National Key Research and Development Program of China (2021YFC2501504).

Disclosure

The authors report no conflicts of interest in this work.

References

- 1. Abad VC, Guilleminault C. Diagnosis and treatment of sleep disorders: a brief review for clinicians. *Dialogues Clin Neurosci*. 2003;5(4):371–388. doi:10.31887/DCNS.2003.5.4/vabad
- 2. Zhou SJ, Wang LL, Yang R, et al. Sleep problems among Chinese adolescents and young adults during the coronavirus-2019 pandemic. *Sleep Med.* 2020;74:39–47. doi:10.1016/j.sleep.2020.06.001
- Smith MT, McCrae CS, Cheung J, et al. Use of actigraphy for the evaluation of sleep disorders and circadian rhythm sleep-wake disorders: an American academy of sleep medicine systematic review, meta-analysis, and GRADE assessment. JCSM. 2018;14(7):1209–1230. doi:10.5664/ jcsm.7228
- 4. Marino M, Li Y, Rueschman MN, et al. Measuring sleep: accuracy, sensitivity, and specificity of wrist actigraphy compared to polysomnography. *Sleep.* 2013;36(11):1747–1755. doi:10.5665/sleep.3142
- 5. Rundo JV, Downey R 3rd. Polysomnography. Handb Clin Neurol. 2019;160:381-392. doi:10.1016/b978-0-444-64032-1.00025-4
- 6. Hirshkowitz M. Polysomnography challenges. Sleep Med Clin. 2016;11(4):403-411. doi:10.1016/j.jsmc.2016.07.002
- Thomas RJ, Mietus JE, Peng CK, Goldberger AL. An electrocardiogram-based technique to assess cardiopulmonary coupling during sleep. 2005;28(9):1151–1161. doi:10.1093/sleep/28.9.1151
- Sun BB, Cao F, Wang Z, Xi F, Yan XW, Ma LJ. Application of bracelet oximetry in the diagnosis of obstructive sleep apnea hypopnea syndrome. *J Chin Pract Diag Ther.* 2017;31(10):975–978.
- 9. Camargos EF, Louzada FM, Nóbrega OT. Wrist actigraphy for measuring sleep in intervention studies with Alzheimer's disease patients: application, usefulness, and challenges. *Sleep Med Rev.* 2013;17(6):475–488. doi:10.1016/j.smrv.2013.01.006
- 10. Widome R, Berger AT, Iber C, et al. Association of delaying school start time with sleep duration, timing, and quality among adolescents. *JAMA Pediatr.* 2020;174(7):697–704. doi:10.1001/jamapediatrics.2020.0344
- 11. Qazi T, Smith A, Alexander M, et al. Disparities in objective sleep quality as assessed through wrist actigraphy in minority patients with inflammatory bowel disease. *Inflamm Bowel Dis.* 2021;27(3):371–378. doi:10.1093/ibd/izaa106
- 12. Teti DM, Whitesell CJ, Mogle JA, et al. Sleep duration and kindergarten adjustment. Pediatrics. 2022;150(2). doi:10.1542/peds.2021-054362
- Quante M, Kaplan ER, Cailler M, et al. Actigraphy-based sleep estimation in adolescents and adults: a comparison with polysomnography using two scoring algorithms. *Nat Sci Sleep*. 2018;10:13–20. doi:10.2147/nss.S151085
- 14. Martin JL, Hakim AD. Wrist actigraphy. Chest. 2011;139(6):1514-1527. doi:10.1378/chest.10-1872
- 15. Arora T, Omar OM, Taheri S. Assessment for the possibility of a first night effect for wrist actigraphy in adolescents. *BMJ open.* 2016;6(10): e012172. doi:10.1136/bmjopen-2016-012172
- 16. Wang H, He L, Gao Y, Gao X, Lei X. Effects of physical activity and sleep quality on well-being: a wrist actigraphy study during the pandemic. *Appl Psychol Health Well Being*. 2021;13(2):394–405. doi:10.1111/aphw.12255
- 17. Cheng P, Walch O, Huang Y, et al. Predicting circadian misalignment with wearable technology: validation of wrist-worn actigraphy and photometry in night shift workers. *Sleep*. 2021;44(2). doi:10.1093/sleep/zsaa180
- 18. Bliwise DL, Chapple C, Maislisch L, Roitmann E, Burtea T. A multitrait, multimethod matrix approach for a consumer-grade wrist-worn watch measuring sleep duration and continuity. *Sleep*. 2021;44(1). doi:10.1093/sleep/zsaa141
- 19. Sadeh A, Hauri PJ, Kripke DF, Lavie P. The role of actigraphy in the evaluation of sleep disorders. *Sleep.* 1995;18(4):288–302. doi:10.1093/sleep/ 18.4.288
- Middelkoop HA, Knuistingh Neven A, van Hilten JJ, Ruwhof CW, Kamphuisen HA. Wrist actigraphic assessment of sleep in 116 community based subjects suspected of obstructive sleep apnoea syndrome. *Thorax*. 1995;50(3):284–289. doi:10.1136/thx.50.3.284
- 21. Ancoli-Israel S, Cole R, Alessi C, Chambers M, Moorcroft W, Pollak CP. The role of actigraphy in the study of sleep and circadian rhythms. *Sleep*. 2003;26(3):342–392. doi:10.1093/sleep/26.3.342
- 22. Quan SF, Howard BV, Iber C, et al. The sleep heart health study: design, rationale, and methods. Sleep. 1997;20(12):1077-1085.
- 23. Zhang GQ, Cui L, Mueller R, et al. The national sleep research resource: towards a sleep data commons. JAMIA. 2018;25(10):1351-1358. doi:10.1093/jamia/ocy064

- 24. Berry RB, Quan SF, Abreu AR; Medicine eaftAAoS. The AASM manual for the scoring of sleep and associated events: rules, terminology and technical specifications. version 2.6. Darien, Illinois: American Academy of Sleep Medicine; 2020.
- 25. Society CT. Guidelines for diagnosis and treatment of obstructive sleep apnea hypopnea syndrome (2011 Revision). *Chin J Tubercul Respir Dis*. 2012;35(1):9–12.
- 26. Johns MW. A new method for measuring daytime sleepiness: the Epworth sleepiness scale. Sleep. 1991;14(6):540-545. doi:10.1093/sleep/14.6.540
- 27. Walker NA, Sunderram J, Zhang P, Lu SE, Scharf MT. Clinical utility of the Epworth sleepiness scale. Sleep Breath. 2020;24(4):1759–1765. doi:10.1007/s11325-020-02015-2
- 28. Griessenberger H, Heib DP, Kunz AB, Hoedlmoser K, Schabus M. Assessment of a wireless headband for automatic sleep scoring. *Sleep Breath*. 2013;17(2):747–752. doi:10.1007/s11325-012-0757-4
- 29. Kosmadopoulos A, Sargent C, Darwent D, Zhou X, Roach GD. Alternatives to polysomnography (PSG): a validation of wrist actigraphy and a partial-PSG system. *Behav Res Methods*. 2014;46(4):1032–1041. doi:10.3758/s13428-013-0438-7
- Toften S, Pallesen S, Hrozanova M, Moen F, Grønli J. Validation of sleep stage classification using non-contact radar technology and machine learning (Somnofy[®]). Sleep Med. 2020;75:54–61. doi:10.1016/j.sleep.2020.02.022
- Zhao R, Xue J, Dong XS, et al. Screening for obstructive sleep apnea using a contact-free system compared with polysomnography. J Clin Sleep Med. 2021;17(5):1075–1082. doi:10.5664/jcsm.9138
- 32. Roach GD, Petrilli RMA, Dawson D, Lamond N. Impact of layover length on sleep, subjective fatigue levels, and sustained attention of long-haul airline pilots. *Chronobiol Int.* 2012;29(5):580–586. doi:10.3109/07420528.2012.675222
- 33. Sargent C, Halson S, Roach GD. Sleep or swim? Early-morning training severely restricts the amount of sleep obtained by elite swimmers. *Eur J Sport Sci.* 2014;14(Suppl 1):S310–S315. doi:10.1080/17461391.2012.696711

Nature and Science of Sleep

Dovepress

Publish your work in this journal

Nature and Science of Sleep is an international, peer-reviewed, open access journal covering all aspects of sleep science and sleep medicine, including the neurophysiology and functions of sleep, the genetics of sleep, sleep and society, biological rhythms, dreaming, sleep disorders and therapy, and strategies to optimize healthy sleep. The manuscript management system is completely online and includes a very quick and fair peer-review system, which is all easy to use. Visit http://www.dovepress.com/testimonials.php to read real quotes from published authors.

Submit your manuscript here: https://www.dovepress.com/nature-and-science-of-sleep-journal